The Investigation of Effects of Tirofiban on Small Intestine Ischemia and Reperfusion Injury

Intestinal ischemia reperfusion (I/R) injury is a significant clinical problem that impacts many remote organ systems, and associated with a high morbidity and mortality. Tirofiban, a glycoprotein IIb/IIIa receptor inhibitor, shows protective effects on I/R experimental models. The aim of the present study was to investigate the possible effects of tirofiban on intestinal I/R injury. 24 male Wistar albino rats were divided into 3 experimental groups. Rats in the control group (n=8) were subjected to laparotomy without artery occlusion, Rats in the I/R group (n = 8) were subjected to occlusion of superior mesenteric artery for 30 min and 3h reperfusion. Rats in the I/R+Tirofiban group (n = 8) were subjected to I/R and received intravenously 200 μg/kg before reperfusion. At the end of experiment terminal ileum tissues collected and analyzed histopathological changes, lipid peroxidation levels, reduced glutathion (GSH) levels and myeloperoxidase (MPO) activity. Intestinal tissue histopathological damage scores, the activity of MPO and the level of malondialdehide (MDA) showed a significant increase in the I/R group as compared with the control group. GSH levels showed reduction in the I/R group as compared with the control group. However, I/R+Tirofiban group has no statistically differences as compared with the I/R group for all evaluated parameters. In conclusion, tirofiban treatment was not able to attaunate or prevent the I/R induced intestinal injury in rats